These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29596984)

  • 21. Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria.
    Black CJ; Yiannakou Y; Houghton LA; Ford AC
    Clin Gastroenterol Hepatol; 2020 Feb; 18(2):392-398.e2. PubMed ID: 31154027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exocrine Pancreatic Insufficiency is Undiagnosed in Some Patients with Diarrhea-Predominant Irritable Bowel Syndrome Using the Rome IV Criteria.
    Olmos JI; Piskorz MM; Litwin N; Schaab S; Tevez A; Bravo-Velez G; Uehara T; Hashimoto H; Rey E; Sorda JA; Olmos JA
    Dig Dis Sci; 2022 Dec; 67(12):5666-5675. PubMed ID: 35704255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome.
    Barberio B; Houghton LA; Yiannakou Y; Savarino EV; Black CJ; Ford AC
    Am J Gastroenterol; 2021 Feb; 116(2):362-371. PubMed ID: 33009062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial.
    Anderle K; Wolzt M; Moser G; Keip B; Peter J; Meisslitzer C; Gouya G; Freissmuth M; Tschegg C
    World J Gastroenterol; 2022 Dec; 28(46):6573-6588. PubMed ID: 36569277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care.
    Ford AC; Bercik P; Morgan DG; Bolino C; Pintos-Sanchez MI; Moayyedi P
    Gastroenterology; 2013 Dec; 145(6):1262-70.e1. PubMed ID: 23994201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Willingness to pay for medications among patients with Rome IV Irritable Bowel Syndrome.
    Goodoory VC; Ng CE; Black CJ; Ford AC
    Neurogastroenterol Motil; 2023 Feb; 35(2):e14483. PubMed ID: 36178331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome.
    Vijayvargiya P; Camilleri M; Burton D; Busciglio I; Lueke A; Donato LJ
    Aliment Pharmacol Ther; 2019 Mar; 49(6):744-758. PubMed ID: 30740753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A trial-based economic evaluation of peppermint oil for the treatment of irritable bowel syndrome.
    Weerts ZZRM; Essers BAB; Jonkers DMAE; Willems JIA; Janssen DJPA; Witteman BJM; Clemens CHM; Westendorp A; Masclee AAM; Keszthelyi D
    United European Gastroenterol J; 2021 Nov; 9(9):997-1006. PubMed ID: 34468079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go?
    Nemakayala DR; Cash BD
    Curr Opin Gastroenterol; 2019 Jan; 35(1):58-62. PubMed ID: 30407259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptomatic overlap in patients with diarrhea predominant irritable bowel syndrome and microscopic colitis in a sub group of Bangladeshi population.
    Rahman MA; Raihan AS; Ahamed DS; Masud H; Safiullah AB; Khair KB; Salimullah AS; Islam MM
    Bangladesh Med Res Counc Bull; 2012 Apr; 38(1):33-8. PubMed ID: 22545349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Irritable bowel syndrome in the Russian Federation: results of the ROMERUS multicenter observational study].
    Maev IV; Okhlobystina OZ; Khalif IL; Andreev DN
    Ter Arkh; 2023 Feb; 95(1):38-51. PubMed ID: 37167114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation Between Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease Based on Fecal Scent: Proof of Principle Study.
    Bosch S; van Gaal N; Zuurbier RP; Covington JA; Wicaksono AN; Biezeveld MH; Benninga MA; Mulder CJ; de Boer NKH; de Meij TGJ
    Inflamm Bowel Dis; 2018 Oct; 24(11):2468-2475. PubMed ID: 29788410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.
    Pimentel M; Morales W; Rezaie A; Marsh E; Lembo A; Mirocha J; Leffler DA; Marsh Z; Weitsman S; Chua KS; Barlow GM; Bortey E; Forbes W; Yu A; Chang C
    PLoS One; 2015; 10(5):e0126438. PubMed ID: 25970536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study.
    Goodoory VC; Houghton LA; Yiannakou Y; Black CJ; Ford AC
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):569-577.e3. PubMed ID: 33957271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients suspected of irritable bowel syndrome--cross-sectional study exploring the sensitivity of Rome III criteria in primary care.
    Engsbro AL; Begtrup LM; Kjeldsen J; Larsen PV; de Muckadell OS; Jarbøl DE; Bytzer P
    Am J Gastroenterol; 2013 Jun; 108(6):972-80. PubMed ID: 23419383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea.
    Buono JL; Carson RT; Flores NM
    Health Qual Life Outcomes; 2017 Feb; 15(1):35. PubMed ID: 28196491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care.
    Black CJ; Craig O; Gracie DJ; Ford AC
    Gut; 2021 Jun; 70(6):1110-1116. PubMed ID: 32973070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea.
    Abel JL; Carson RT; Andrae DA
    Qual Life Res; 2019 Feb; 28(2):369-377. PubMed ID: 30267294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.